Aytu BIOPHARMA, Inc. (AYTU) intrinsic value & 10-year financials
Aytu BIOPHARMA, Inc. (AYTU) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 43.6% a year to $66.4M, with an average return on invested capital of -80.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.04
- Market cap
- $6.8M
- Revenue (FY2025)
- $66.4M
- Revenue growth (10-yr CAGR)
- 43.6%
- ROIC (10-yr avg)
- -80.1%
- Free cash flow (FY2025)
- -$2.2M
AYTU 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $66.4M | -$13.6M | — | -$2.2M | -11.8% | -73.8% |
| FY2024 | $81.0M | -$15.8M | — | -$1.7M | -6.5% | -20.4% |
| FY2023 | $107.4M | -$17.1M | -$5.11 | — | -15.9% | -47.2% |
| FY2022 | $96.7M | -$110.2M | -$3.75 | -$28.8M | -115.4% | -172.5% |
| FY2021 | $65.6M | -$58.3M | -$3.48 | -$28.3M | -89.7% | -87.2% |
| FY2020 | $27.6M | -$13.6M | — | -$28.4M | -76.5% | -98.3% |
| FY2019 | $7.3M | -$27.1M | — | -$13.9M | -230.1% | 425.8% |
| FY2018 | $3.7M | -$10.2M | — | -$16.0M | -538.2% | -226.1% |
| FY2017 | $3.2M | -$22.5M | — | -$13.9M | -624.7% | -285.8% |
| FY2016 | $2.6M | -$28.2M | — | -$10.9M | -847.0% | -215.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
AYTU BIOPHARMA, INC is a consistent compounder, expanding top-line revenue at 43.6% annually over the past decade.
AYTU BIOPHARMA, INC has historically struggled to out-earn its cost of capital, averaging just -33.2% ROIC.
AYTU BIOPHARMA, INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, AYTU BIOPHARMA, INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-134.88 per share.